Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ivosidenib (AG-120)
ivosidenib · 1 trial · 1 indication
AG-120 Area Under the Curve
AG-120 Maximum Plasma Concentration
| Arm | Type | Description |
|---|---|---|
| ivosidenib (AG-120) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ivosidenib (AG-120) | DRUG | A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects |
Inclusion Criteria: * Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years. * Applicable to Caucasian Subjects Only: Non-Japanese subjects must be Caucas...
Ivosidenib is a small molecule drug candidate developed by Agios Pharmaceuticals, Inc. (ticker AGIO). It is an inhibitor of the IDH1 molecular target. The program is in Phase 1 clinical development, and the specific patient indications being studied have not been disclosed. It is also known as ivosidenib (AG-120).
Ivosidenib targets IDH1, an isocitrate dehydrogenase enzyme. It is classified as an inhibitor of this molecular target. By inhibiting IDH1, the drug is designed to interfere with the enzyme's activity. The IDH1 target is the basis for its development as a small molecule therapeutic candidate.
Ivosidenib is developed by Agios Pharmaceuticals, Inc., which trades under the ticker symbol AGIO. Agios is the company responsible for the clinical program for ivosidenib, also referred to as AG-120. The drug is a small molecule IDH1 inhibitor in Phase 1 development.
Ivosidenib is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes a completed bridging study in healthy subjects. The drug remains under clinical evaluation as a small molecule IDH1 inhibitor.
Ivosidenib has been studied in a Phase 1 trial, NCT03071770, titled Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects. This trial was completed and enrolled 60 healthy male volunteers aged 18 years and older in the United States. It was an uncontrolled study.
Yes, ivosidenib is also known as AG-120. The alternative name AG-120 refers to the same small molecule IDH1 inhibitor developed by Agios Pharmaceuticals, Inc. (AGIO). Both names are used interchangeably in reference to this Phase 1 investigational drug candidate.